BSX
Boston Scientific Corporation
NYSEUSDEQUITY
Healthcare
DELAYED
Sell
-40/100
Last price
42.27
▼ 0.13 (0.31%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
42.49
Prev close
42.40
Day high
42.75
Day low
42.00
Volume
12.55M
Market cap
$61.14B
P/E (TTM)
17.15
52W range
41.94 – 105.65
Day trading desk
Gap from prior close
+0.21%
Prior close 42.40
VWAP
42.29
-0.06% from price
Relative volume
1.47×
Normal
Session range
6.37%
40.19 – 42.75
Position in range
81%
Near session high
ATR (14D)
1.09
2.57% of price
Prior day high
43.30
PDH
Prior day low
42.29
PDL
Bid / ask spread
—
Quote not published
Session volume
28.99M
Avg 19.67M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-3.85%
-5.8%
1M
-11.74%
-12.9%
3M
-5.85%
-10.4%
6M
-31.80%
-50.0%
YTD
-55.75%
-70.0%
1Y
-56.65%
-73.1%
3Y
-20.09%
-102.3%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on BSX open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
3.68M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 2, 26 | O'CONNOR PADRAIG ANDREW Officer |
— | 1.17K | — | Direct |
| Aug 25, 26 | MORANO SUSAN E. Director |
BUY | 2.04K | $100.41K | Direct |
| Aug 5, 26 | HABIGER DAVID C Director |
BUY | 2.10K | $99.94K | Direct |
| Aug 4, 26 | HABIGER DAVID C Director |
BUY | 1.18K | $56.89K | Direct |
| Aug 3, 26 | MAHONEY MICHAEL F Chief Executive Officer |
BUY | 186.24K | $9.00M | Direct |
| Jul 31, 26 | LUDWIG EDWARD J. Director |
BUY | 5.00K | $227.40K | Direct |
| Jul 1, 26 | MONSON JONATHAN R Chief Financial Officer |
— | 2.09K | — | Direct |
| May 28, 26 | MAHONEY MICHAEL F Chief Executive Officer |
STOCK | 386.75K | $0 | Indirect |
| May 20, 26 | LUDWIG EDWARD J. Director |
BUY | 3.58K | $202.91K | Direct |
| May 20, 26 | HABIGER DAVID C Director |
BUY | 4.45K | $251.10K | Direct |
| May 20, 26 | PEGUS CHERYL Director |
BUY | 1.77K | $99.99K | Direct |
| May 7, 26 | LUDWIG EDWARD J. Director |
STOCK | 3.80K | $0 | Direct |
| May 7, 26 | MEGA JESSICA L M.D. Director |
STOCK | 3.80K | $0 | Direct |
| May 7, 26 | MORANO SUSAN E. Director |
STOCK | 5.08K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BRENNAN DANIEL J |
Chief Financial Officer | 225.81K | Sale |
BROWN VANCE R |
General Counsel | 54.24K | Conversion of Exercise of derivative security |
BUTCHER ARTHUR C |
Officer | 77.11K | Conversion of Exercise of derivative security |
CARRUTHERS WENDY |
Officer | 29.31K | Sale |
FITZGERALD JOSEPH MICHAEL |
Officer | 219.14K | Conversion of Exercise of derivative security |
LUDWIG EDWARD J. |
Director | 30.36K | Purchase |
MAHONEY MICHAEL F |
Chief Executive Officer | 1.61M | Purchase |
MONSON JONATHAN R |
Chief Financial Officer | 39.06K | Conversion of Exercise of derivative security |
SUNUNU JOHN E |
Director | 54.72K | Stock Award(Grant) |
WICHMANN DAVID S |
Director | 45.38K | Stock Award(Grant) |
Fundamentals
Market cap$61.14B
Enterprise value$73.47B
Revenue (TTM)$21.00B
Gross profit$14.53B
EBITDA$5.71B
Net income$3.67B
EPS (TTM)$2.46
Free cash flow$2.45B
Total cash$539.00M
Total debt$12.62B
Book value / share$17.23
Shares outstanding1.45B
Float1.44B
Short % of float3.21%
Dividend yield0.00%
Beta (5Y)0.58
Valuation & profitability ratios
Trailing P/E17.15
Forward P/E12.40
PEG ratio0.59
Price / sales—
Price / book2.45
EV / revenue3.50
EV / EBITDA12.87
Gross margin69.19%
Operating margin22.90%
Profit margin17.50%
Return on equity15.34%
Return on assets6.19%
Debt / equity50.15
Current ratio1.24
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $20.07B | $16.75B | $14.24B | $12.68B | +19.9% |
| Operating revenue | $20.07B | $16.75B | $14.24B | $12.68B | +19.9% |
| Cost of revenue | $6.22B | $5.26B | $4.34B | $3.96B | +18.3% |
| Gross profit | $13.85B | $11.49B | $9.89B | $8.73B | +20.6% |
| Research & development | $2.05B | $1.61B | $1.41B | $1.32B | +27.1% |
| Selling, general & admin | $6.89B | $5.98B | $5.19B | $4.52B | +15.1% |
| Total operating expense | $9.88B | $8.49B | $7.48B | $6.69B | +16.4% |
| Operating income | $3.97B | $3.00B | $2.42B | $2.03B | +32.3% |
| Net interest income | -$320.00M | -$198.00M | -$243.00M | -$460.00M | -61.6% |
| Pre-tax income | $3.38B | $2.28B | $1.99B | $1.14B | +48.3% |
| Tax provision | $493.00M | $436.00M | $393.00M | $443.00M | +13.1% |
| Net income | $2.90B | $1.85B | $1.59B | $698.00M | +56.3% |
| Net income to common | $2.90B | $1.85B | $1.57B | $642.00M | +56.4% |
| Basic EPS | 1.96 | 1.26 | 1.08 | 0.45 | +55.6% |
| Diluted EPS | 1.94 | 1.25 | 1.07 | 0.45 | +55.2% |
| EBIT | $3.73B | $2.59B | $2.25B | $1.61B | +44.3% |
| EBITDA | $5.10B | $3.86B | $3.45B | $2.75B | +32.3% |
| Basic shares | 1.48B | 1.47B | 1.45B | 1.43B | +0.6% |
| Diluted shares | 1.49B | 1.49B | 1.46B | 1.44B | +0.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $1.97B | $414.00M | $865.00M | $928.00M | +374.6% |
| Cash & short-term investments | $1.97B | $414.00M | $865.00M | $928.00M | +374.6% |
| Accounts receivable | $2.93B | $2.56B | $2.23B | $1.97B | +14.4% |
| Inventory | $2.94B | $2.81B | $2.48B | $1.87B | +4.7% |
| Total current assets | $8.79B | $6.92B | $6.51B | $5.76B | +27.1% |
| Property, plant & equipment | $4.04B | $3.29B | $3.30B | $2.83B | +22.5% |
| Goodwill & intangibles | $25.30B | $23.77B | $20.39B | $18.82B | +6.4% |
| Total assets | $43.67B | $39.40B | $35.14B | $32.47B | +10.9% |
| Total current liabilities | $5.44B | $6.40B | $4.93B | $3.80B | -15.0% |
| Current debt | $299.00M | $1.78B | $531.00M | $20.00M | -83.2% |
| Long-term debt | $11.01B | $8.84B | $8.57B | $8.91B | +24.5% |
| Total debt | $11.44B | $10.75B | $9.49B | $9.28B | +6.4% |
| Total liabilities | $19.20B | $17.39B | $15.61B | $14.90B | +10.4% |
| Retained earnings | $5.57B | $2.67B | $819.00M | -$750.00M | +108.4% |
| Shareholder equity | $24.23B | $21.77B | $19.28B | $17.57B | +11.3% |
| Working capital | $3.35B | $521.00M | $1.58B | $1.96B | +544.0% |
| Net tangible assets | -$1.07B | -$2.00B | -$1.11B | -$1.25B | +46.6% |
| Shares issued | 1.75B | 1.74B | 1.73B | 1.70B | +0.5% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | $2.89B | $1.85B | $1.59B | $698.00M | — | +56.7% |
| Depreciation & amortisation | $1.37B | $1.27B | $1.20B | $1.14B | — | +7.8% |
| Stock-based compensation | $299.00M | $266.00M | $233.00M | $220.00M | — | +12.4% |
| Change in working capital | -$246.00M | -$462.00M | -$770.00M | -$1.00B | — | +46.8% |
| Operating cash flow | $4.53B | $3.44B | $2.50B | $1.53B | — | +32.0% |
| Capital expenditure | -$1.13B | -$1.07B | -$800.00M | -$612.00M | — | -5.6% |
| Investing cash flow | -$2.64B | -$5.69B | -$2.57B | -$2.01B | — | +53.6% |
| Share buybacks | — | — | — | $0 | $0 | — |
| Dividends paid | — | $0 | -$28.00M | -$55.00M | -$55.00M | — |
| Financing cash flow | -$395.00M | $1.81B | $5.00M | -$548.00M | — | -121.8% |
| Free cash flow | $3.40B | $2.37B | $1.70B | $914.00M | — | +43.9% |
| End cash position | $2.15B | $606.00M | $1.05B | $1.13B | — | +254.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $5.44B | $5.20B | $5.29B | $5.07B | $5.06B | +4.6% |
| Operating revenue | $5.44B | $5.20B | $5.29B | $5.07B | $5.06B | +4.6% |
| Cost of revenue | $1.59B | $1.59B | $1.61B | $1.52B | $1.64B | +0.3% |
| Gross profit | $3.85B | $3.61B | $3.68B | $3.54B | $3.42B | +6.5% |
| Research & development | $554.00M | $516.00M | $569.00M | $514.00M | $526.00M | +7.4% |
| Selling, general & admin | $1.80B | $1.78B | $1.83B | $1.74B | $1.72B | +1.2% |
| Total operating expense | $2.60B | $2.54B | $2.64B | $2.49B | $2.48B | +2.4% |
| Operating income | $1.25B | $1.07B | $1.04B | $1.05B | $943.00M | +16.2% |
| Net interest income | -$96.00M | -$90.00M | -$61.00M | -$87.00M | -$90.00M | -6.7% |
| Pre-tax income | $1.06B | $1.16B | $700.00M | $939.00M | $941.00M | -8.8% |
| Tax provision | $155.00M | -$176.00M | $30.00M | $183.00M | $146.00M | +188.1% |
| Net income | $907.00M | $1.34B | $672.00M | $755.00M | $797.00M | -32.4% |
| Net income to common | $907.00M | $1.34B | $672.00M | $755.00M | $797.00M | -32.4% |
| Basic EPS | 0.62 | 0.90 | 0.45 | 0.51 | 0.54 | -31.1% |
| Diluted EPS | 0.61 | 0.90 | 0.45 | 0.51 | 0.53 | -32.2% |
| EBIT | $1.16B | $1.25B | $790.00M | $1.03B | $1.03B | -7.7% |
| EBITDA | $1.51B | $1.60B | $1.16B | $1.37B | $1.37B | -5.7% |
| Basic shares | 1.47B | 1.48B | 1.48B | 1.48B | 1.48B | -1.0% |
| Diluted shares | 1.47B | 1.50B | 1.50B | 1.50B | 1.49B | -1.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $539.00M | $1.45B | $1.97B | $1.27B | $534.00M | -62.9% |
| Cash & short-term investments | $539.00M | $1.45B | $1.97B | $1.27B | $534.00M | -62.9% |
| Accounts receivable | $3.05B | $3.03B | $2.93B | $2.83B | $2.81B | +0.7% |
| Inventory | $3.23B | $3.12B | $2.94B | $2.92B | $2.86B | +3.8% |
| Total current assets | $7.97B | $8.68B | $8.79B | $8.04B | $7.12B | -8.2% |
| Property, plant & equipment | $4.13B | $4.06B | $4.04B | $4.29B | $3.95B | +1.6% |
| Goodwill & intangibles | $25.56B | $25.60B | $25.30B | $25.38B | $25.34B | -0.2% |
| Total assets | $45.22B | $44.35B | $43.67B | $42.71B | $41.56B | +2.0% |
| Total current liabilities | $6.43B | $4.57B | $5.44B | $5.33B | $5.19B | +40.6% |
| Current debt | $1.71B | $41.00M | $299.00M | $483.00M | $480.00M | +4,068.3% |
| Long-term debt | $10.79B | $10.86B | $11.01B | $10.99B | $10.98B | -0.7% |
| Total debt | $12.62B | $11.03B | $11.44B | $12.05B | $12.03B | +14.5% |
| Total liabilities | $20.04B | $18.25B | $19.20B | $19.08B | $18.91B | +9.8% |
| Retained earnings | $7.82B | $6.91B | $5.57B | $4.90B | $4.14B | +13.1% |
| Shareholder equity | $24.93B | $25.86B | $24.23B | $23.39B | $22.42B | -3.6% |
| Working capital | $1.54B | $4.11B | $3.35B | $2.71B | $1.93B | -62.5% |
| Net tangible assets | -$628.00M | $267.00M | -$1.07B | -$1.98B | -$2.92B | -335.2% |
| Shares issued | 1.45B | 1.75B | 1.75B | 1.75B | 1.74B | -17.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | $904.00M | $1.34B | $670.00M | $755.00M | $795.00M | -32.5% |
| Depreciation & amortisation | $355.00M | $351.00M | $365.00M | $342.00M | $336.00M | +1.1% |
| Stock-based compensation | $87.00M | $83.00M | $71.00M | $79.00M | $75.00M | +4.8% |
| Change in working capital | $74.00M | -$915.00M | $155.00M | $44.00M | $233.00M | +108.1% |
| Operating cash flow | $1.47B | $348.00M | $1.36B | $1.34B | $1.29B | +323.6% |
| Capital expenditure | -$1.93B | -$177.00M | -$425.00M | -$196.00M | -$245.00M | -987.6% |
| Investing cash flow | -$1.96B | -$591.00M | -$512.00M | -$502.00M | -$1.13B | -231.0% |
| Financing cash flow | -$410.00M | -$260.00M | -$184.00M | -$104.00M | -$340.00M | -57.7% |
| Free cash flow | -$451.00M | $171.00M | $939.00M | $1.15B | $1.04B | -363.7% |
| End cash position | $753.00M | $1.64B | $2.15B | $1.48B | $741.00M | -54.2% |
Options analytics
Put / call volume
0.72
Call-heavy session
Put / call open interest
0.77
Positioning, not flow
Max pain
43.50
+3.1% from spot
ATM implied vol
42.8%
Nearest strike to spot
Skew (10% OTM)
-28.5%
Calls bid over puts
Call volume
1.19K
Contracts, this expiry
Put volume
859
Contracts, this expiry
Heaviest call OI
46.50
840 contracts
Heaviest put OI
43.50
977 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 0.83 | 0.86 | +3.9% |
| Mar 2026 | 0.79 | 0.80 | +1.6% |
| Dec 2025 | 0.78 | 0.80 | +2.4% |
| Sep 2025 | 0.71 | 0.75 | +5.1% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 0.76 | 22 | $5.12B | +1.1% |
| Next quarter | 0.84 | 20 | $5.41B | +2.3% |
| Current year | 3.26 | 25 | $21.19B | +5.6% |
| Next year | 3.38 | 25 | $22.20B | +4.8% |
Analyst targets & ownership
Mean target$60.32
High target$94.00
Low target$44.00
Implied upside42.71%
Analyst count28
ConsensusBUY
Strong buy / Buy7 / 18
Hold5
Sell / Strong sell0 / 0
Held by insiders0.25%
Held by institutions95.31%
Institutions holding2.19K
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
43.53
-2.90% from price
SMA 20
43.73
-3.53% from price
SMA 50
46.77
-9.80% from price
SMA 100
47.03
-10.13% from price
SMA 200
61.22
-31.08% from price
EMA 12
43.43
-2.68% from price
EMA 26
44.52
-5.05% from price
EMA 50
45.82
-7.75% from price
RSI (14)
34.4
Neutral
MACD (12,26,9)
-1.08
Hist -0.07
ATR (14)
1.09
2.58% of price
Realised vol 30D
34.3%
Annualised
Bollinger upper
45.37
20, 2σ
Bollinger lower
42.09
20, 2σ
50 / 200 cross
Death
46.77 vs 61.22
Trend bias
Below 200
-31.08%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.19
Less volatile than market
Correlation to SPY
0.06
Largely independent
Realised vol 30D
34.3%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-59.8%
Peak to trough
Max drawdown 5Y
-61.0%
Peak to trough
ATR 14
1.09
2.58% of price
Beta (reported)
0.58
5Y monthly, from filing
Short interest
Shares short
46.50M
Prior 27.62M
Change vs prior
+68.4%
Shorts adding
% of float
3.21%
Normal
% of shares out
3.21%
Against total outstanding
Days to cover
2.3
Liquid
Float
1.44B
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 5, 26 | Citigroup | MAINTAINED | Neutral | Neutral |
| Sep 24, 26 | Wells Fargo | MAINTAINED | Equal-Weight | Equal-Weight |
| Sep 21, 26 | Oppenheimer | MAINTAINED | Outperform | Outperform |
| Sep 17, 26 | Citigroup | DOWNGRADE | Buy | Neutral |
| Sep 9, 26 | BTIG | MAINTAINED | Buy | Buy |
| Aug 25, 26 | TD Cowen | MAINTAINED | Buy | Buy |
| Jul 31, 26 | Argus Research | DOWNGRADE | Buy | Hold |
| Jul 30, 26 | UBS | MAINTAINED | Buy | Buy |
| Jul 30, 26 | Citigroup | MAINTAINED | Buy | Buy |
| Jul 30, 26 | RBC Capital | MAINTAINED | Outperform | Outperform |
| Jul 30, 26 | TD Cowen | MAINTAINED | Buy | Buy |
| Jul 30, 26 | Canaccord Genuity | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split2:1
Split dateNov 6, 2003
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-23
Corporate Changes & Voting Matters
8-K · 2026-09-08
Corporate Changes & Voting Matters
8-K · 2026-08-26
Periodic Financial Reports
10-Q · 2026-08-03
Corporate Changes & Voting Matters
8-K · 2026-07-29
Corporate Changes & Voting Matters
8-K · 2026-07-27
Annual report of employee stock purchase
11-K · 2026-06-24
Specialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)
SD · 2026-05-21
Headlines
Stryker (SYK) vs Boston Scientific (BSX): Which is a Better Stock to Buy?
Insider Monkey · 4h ago
Zenflow raises $52M, inks distribution deal with Cook Medical
MedTech Dive · 10h ago
Can J&J's MedTech Business Rebound in Q3 After Q2 Slowdown?
Zacks · 13h ago
If The MiniMed Split-Off Stalls, What Happens To Your Medtronic Stock?
Trefis · 16h ago
Citigroup Adjusts Price Target on Boston Scientific to $48 From $50, Keeps Neutral Rating
MT Newswires · 2d ago
2 Cash-Producing Stocks Worth Investigating and 1 That Underwhelm
StockStory · 2d ago
Medtronic’s 49-Year Dividend Streak Faces a New Challenge: Is Growth Finally the Real Story?
24/7 Wall St. · 4d ago
Boston Scientific (BSX) Stock Sinks As Market Gains: What You Should Know
Zacks · 4d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.